Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 80

Results For "Score"

847 News Found

DiscGenics presents positive Phase1/2 study of Cell therapy for degenerative disc disease
Biotech | February 27, 2022

DiscGenics presents positive Phase1/2 study of Cell therapy for degenerative disc disease

Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection


VBI’s 3-antigen Hepatitis B vaccine gets CHMP nod
Biotech | February 27, 2022

VBI’s 3-antigen Hepatitis B vaccine gets CHMP nod

If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.


Philips on track with its ESG  commitments
Sustainability | February 24, 2022

Philips on track with its ESG commitments

Circular revenues already at 16% of sales, driven by healthcare informatics and services to enhance medical equipment uptime and utilization, system and software upgrades for enhanced functionality and extended lifetime and reusing refurbished parts and systems


Enhertu Phase III results to redefine how metastatic breast cancer is classifed
Biotech | February 21, 2022

Enhertu Phase III results to redefine how metastatic breast cancer is classifed

Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.


Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
News | February 19, 2022

Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'

Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).


PerkinElmer’s SIRION Biotech and CRG to develop diabetes gene therapy
Biotech | February 17, 2022

PerkinElmer’s SIRION Biotech and CRG to develop diabetes gene therapy

Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy


USFDA accepts for Priority Review Bristol Myers Squibb’s Supplemental BLA for Breyanzi
Biotech | February 17, 2022

USFDA accepts for Priority Review Bristol Myers Squibb’s Supplemental BLA for Breyanzi

Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years


Rapid Medical receives USFDA designation for Comaneci
Medical Device | February 16, 2022

Rapid Medical receives USFDA designation for Comaneci

The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke


Avion Pharmaceuticals announces USFDA approval of DHIVY
Drug Approval | February 15, 2022

Avion Pharmaceuticals announces USFDA approval of DHIVY

Parkinson's disease treatment is the first and only carbidopa/levodopa (CD/LD) tablet designed to be divided for precise dosing


Dr. Reddy’s impresses on sustainability and gender equality again
Sustainability | February 03, 2022

Dr. Reddy’s impresses on sustainability and gender equality again

Dr. Reddy’s included in S&P Global’s Sustainability Yearbook for the 2nd year and Bloomberg Gender-Equality Index for the 5th year in a row